Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression: A Randomized Placebo-Controlled Clinical Trial
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This study investigates the impact of perioperative inhibition of beta-adrenergic and COX-2 signaling in ovarian cancer patients undergoing debulking surgery. The trial aims to assess the feasibility, safety, and biological effects of a combination of propranolol and etodolac in reducing cancer metastasis and improving immune responses.
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 20
Maximum Age: 85
Healthy Volunteers: f
View:
• Age 20-85
• ASA score 1-3 or ECOG Performance Status of 0 to 2
• Patients with a suspected high-grade ovarian epithelial cancer based on imaging, clinical examination, CA125, and/or tumor biopsy
• Patients planned for surgery for primary surgery, or interval debulking surgery for ovarian cancer
• Signed informed consent form
• Willing and able to comply with study procedures (physically and mentally)
Locations
Other Locations
Israel
The Chaim Sheba Medical Center
RECRUITING
Ramat Gan
Tel Aviv Sourasky Medical Center (Ichilov Hospital)
RECRUITING
Tel Aviv
Contact Information
Primary
Shamgar Ben-Eliyahu, Prof.
shamgar@tauex.tau.ac.il
972-3-6407266
Time Frame
Start Date: 2025-03-12
Estimated Completion Date: 2026-08-31
Participants
Target number of participants: 60
Treatments
Experimental: Intervention Arm
Patients receive propranolol + etodolac (active treatment)
Placebo_comparator: Placebo Arm
Patients receive matching placebo for both drugs
Related Therapeutic Areas
Sponsors
Leads: Tel-Aviv Sourasky Medical Center
Collaborators: The Chaim Sheba Medical Center, National Cancer Institute (NCI)